Genomic analysis identifies unique signatures predictive of brain, lung, and liver relapse by Harrell, J. Chuck et al.
PRECLINICAL STUDY
Genomic analysis identiﬁes unique signatures predictive of brain,
lung, and liver relapse
J. Chuck Harrell • Aleix Prat • Joel S. Parker •
Cheng Fan • Xiaping He • Lisa Carey •
Carey Anders • Matthew Ewend • Charles M. Perou
Received: 27 May 2011/Accepted: 28 May 2011/Published online: 14 June 2011
 Springer Science+Business Media, LLC. 2011
Abstract The ability to predict metastatic potential could
be of great clinical importance, however, it is uncertain if
predicting metastasis to speciﬁc vital organs is feasible. As
a ﬁrst step in evaluating metastatic predictions, we ana-
lyzed multiple primary tumors and metastasis pairs and
determined that [90% of 298 gene expression signatures
were found to be similarly expressed between matched
pairs of tumors and metastases; therefore, primary tumors
may be a good predictor of metastatic propensity. Next,
using a dataset of [1,000 human breast tumor gene
expression microarrays we determined that HER2-enriched
subtype tumors aggressively spread to the liver, while
basal-like and claudin-low subtypes colonize the brain and
lung. Correspondingly, brain and lung metastasis signa-
tures, along with embryonic stem cell, tumor initiating cell,
and hypoxia signatures, were also strongly expressed in the
basal-like and claudin-low tumors. Interestingly, low
‘‘Differentiation Scores,’’ or high expression of the afore-
mentioned signatures, further predicted for brain and lung
metastases. In total, these data identify that depending upon
the organ of relapse, a combination of gene expression
signatures most accurately predicts metastatic behavior.
Keywords Breast cancer  Gene expression 
Intrinsic subtype  Metastasis  Microarray
Introduction
The vast majority of deaths due to breast cancer for nearly
half a million people annually worldwide are due to distant
metastases in the lung, liver, and brain [1]. Numerous
studies have focused on breast cancer metastases and how
they might differ from primary breast tumors; however,
controversy remains regarding (A) the predisposition of
speciﬁc classes of breast tumors to spread to distant sites
and (B) the degree of similarity between primary breast
tumors and their associated metastases.
Estrogen receptor (ER) status is known to be associated
with breast cancer relapse in speciﬁc organs [2]. In 2008,
this organ selectivity was reﬁned by contrasting relapse
patterns in 344 patients who had their tumors genomically
subtyped as luminal A or B, HER2-enriched, basal-like, or
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DOI 10.1007/s10549-011-1619-7normal-like [3]. In general, bone metastases were associ-
ated with the luminal subtypes, whereas basal-like and
HER2-enriched tumors were signiﬁcantly associated with
brain and lung relapse. Similar results were also observed
in an immunohistochemical-based study on 3,726 patients
[4]. Recently, a new breast cancer subtype was identiﬁed,
named claudin-low [5–7]. This subtype exhibits aggressive
characteristics including expression of mesenchymal
markers and low expression of genes involved in tight
junctions and cell–cell adhesion. The lack of epithelial cell
features and expression of mesenchymal traits is reminis-
cent of features associated with breast stem cells [8]. Since
breast cancer stem cells are relatively resistant to both
chemotherapy and radiation [9, 10], and because metasta-
ses frequently progress despite treatment, it is important to
determine if these claudin-low/mesenchymal cells are
associated with metastatic potential.
To better understand the biology driving breast cancer
metastases, 1,319 human gene expression microarrays from
primary tumors, metastases, and cancer cell lines were
analyzed here. Tumors and their associated metastases, on
average, were much more similar to each other than they
were different. By including the recently deﬁned claudin-
low subtype we extend previous ﬁndings [3, 4] and better
deﬁne the metastatic predilections of each intrinsic subtype.
Increasingly ‘‘undifferentiated’’ breast cancer cells
[as quantitatively measured by a Differentiation Score pre-
dictor (DS)] tend to express stem cell signatures and pref-
erentially metastasize to the brain and lung. These results
identify that breast cancer intrinsic subtype is maintained
throughout disease progression, and that a combination of
several genomic signatures can add prognostic value and
thereforedirectwherediseasemonitoringshouldbefocused.
Results
Genetic similarity among tumors and metastases
Previously, we examined the genome-wide gene expression
proﬁles of ﬁve primary breast tumor/matched metastatic
pairs and noted an overall high degree of similarity within a
pair [11]. To further examine the degree of relatedness of
breast tumors and their metastases, we performed correla-
tion analysis using thousands of genes, and hundreds of pre-
deﬁned gene expression signatures/modules [12] incorpo-
rating a large set of tumors and paired metastases. Intra-
class correlation (ICC) values were determined between
pairs of samples using multiple classiﬁcation/grouping
methods: (1) different pieces of the same primary tumor
(‘‘intrinsic pairs’’), (2) tumors and their matched metastases
[all metastases, or further separated into either lymph
node (LN) or distant], (3) tumors and their matched
metachronous metastases, (4) sets of synchronous metas-
tases from the same patient, (5) tumors from different
patients grouped by intrinsic subtype, and (6) metastases
from different patients (Fig. 1a). On average when using all
expressed genes, there was high concordance between two
pieces of the same primary tumor (ICC = 0.9 [0.89–0.91]),
while pairs of tumors and their metastases exhibit lower
concordance values (0.82 [0.8–0.83]). As observed by the
metachronously paired tumor-metastasis samples, gene
expression did not change substantially over time. The
autopsy patient data (0.72 [0.68–0.75]) suggest that normal
organ RNA may be the variable most responsible for the
decreased similarity between tumor and metastasis pairs.
This hypothesis was supported by increased ICC values of
20 matched pairs of laser-captured tumors and LN metas-
tases [13] (0.9 [0.85–0.94]).
Individual gene measurements can be fraught with
‘‘noise.’’ Thus, to further test the relationship between
tumors and metastases, ICC values were identiﬁed using a
compendium of 298 different gene expression signatures/
modules [12], where each module is a summary measure of
tens to hundreds of genes. The overall ICC values were
higher than individual genes (thus showing greater
robustness for gene signatures) and the breast tumor–
metastasis pairs showed high conservation of pathways
(Fig. 1b). The signatures with the most variability between
tumors and matched metastases were associated with
extracellular matrix (ECM) proteins. These genes may be
microenvironment-induced or may be due to different
amounts of ﬁbroblasts found in tumors as compared to
metastases (Supplemental Table 1).
Association of subtypes and sites of metastasis
Since the majority of genes maintain their RNA expression
levels when growing as either primary tumors in the breast
or as metastases, we sought to determine if the different
intrinsic subtypes showed a predilection for metastasis to
speciﬁc organs using genomic data arising from primary
tumors only. Therefore, we combined four public micro-
array datasets with Distance Weighted Discrimination [14],
providing 855 tumors with documented ﬁrst site of relapse
(Supplemental Table 2) [15–18]. Principal components
analysis found that the overall variation of gene expression
was due to the biology of the tumors, and not by cohort/
source or microarray platform (Supplemental Fig. 1). Sta-
tus for ER, progesterone receptor (PR), and human epi-
dermal growth factor receptor 2 (HER2) was recorded for
852, 537, and 499 tumors, respectively, and of the 482
tumors with deﬁned status for all three markers, 110 were
triple negative (TN); Kaplan–Meier analyses for site of
relapse with these markers are shown in Supplemental
Fig. 2. For all sites of relapse, ER/PR negativity was
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123associated with increased metastases, except for bone, in
which both ER? and ER- tumors recurred. Clinical
HER2? and TN status were associated with liver and
brain/lung relapse, respectively.
Next, each tumor’s intrinsic subtype was calculated for
this combined data set using the PAM50 [19] and the
claudin-low subtype predictors [6] (Supplemental Table 3).
Of the 855 tumors, 76 were identiﬁed as normal breast-like,
and since this tumor classiﬁcation is reﬂective of mostly
normal breast tissue [19], these tumors/samples were
excluded from further analyses, leaving a dataset of 779
tumors. Based on the site of ﬁrst relapse data for liver,
lung, brain, and bone, Kaplan–Meier plots were generated,
and we determined that intrinsic subtype was correlated
with site of relapse (Fig. 2, Supplemental Fig. 3). Com-
pared to luminal A, basal-like and HER2-enriched tumors
showed the highest hazard ratio (HR) of relapse to any site
(basal-like vs. luminal A hazard ratio [HR] 2.1,
P\0.0001; HER2-enriched vs. luminal A HR 2.0,
P\0.0001) followed by luminal B (HR 1.69, P\0.001)
and claudin-low (HR 1.47, P = 0.051) tumors. Important
ﬁndings included: (1) bone metastasis was the most com-
mon—regardless of subtype (Table 1), (2) brain relapse
occurred most frequently in non-luminal samples, (3) liver
relapse was associated with HER2-enriched tumors, and
(4) lung relapse occurred often within the claudin-low and
basal-like subtypes. In all analyses, luminal B tumors were
more metastatic than luminal A tumors, thus providing a
useful stratiﬁcation within ER? tumors.
Undifferentiated tumors and brain metastases
In 2009, Bos et al. [16] utilized two human breast cancer
cell lines, CN34 and variants of the MDA-MB-231 human
breast cancer cell line (a claudin-low cell line[6]), along
with gene expression data from human breast tumors, to
identify 17 genes whose expression correlated with brain
relapse (BrMS). Given the clear associations observed for
the intrinsic subtypes and sites of metastases, we hypoth-
esized that the BrMS would correlate with basal-like and/or
claudin-low subtypes. ANOVA from two different datasets
supported this hypothesis (Fig. 3a, b). A lung metastasis
signature (LMS) [20] is also associated with intrinsic
subtype (Fig. 3c, d).
Recently, a genomic method to quantify breast epithelial
cell differentiation status, known as the Differentiation
Score (DS) predictor [6] was developed. This predictor is
based on the genomic signatures of FACS puriﬁed popu-
lations of mammary stem cells, luminal progenitors, and
mature luminal cells of the normal human breast [8]. The
scoring of the DS predictor is based on the premise that
mammary stem cells are the least differentiated cells in the
breast and they give rise to luminal progenitors, which then
produce mature luminal cells; for the DS, higher scores
represent greater differentiation along this axis that starts
with the mammary stem cell signature and culminates in
mature ER? luminal cells. In this spectrum, claudin-low
tumors are the least differentiated, followed by basal-like,
HER2-enriched, and ending with luminal B and A tumors
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Fig. 1 Genomic similarity of breast tumors and metastases. Micro-
arrays were performed on 265 primary tumors and 85 metastases and
the overall similarity was measured by intra-class correlation (ICC),
with estimates plotted showing 95% conﬁdence intervals. a Using all
variably expressed genes, gene expression concordance values were
measured in matched samples from the same patient; primary tumors
split in 2 (n = 40), tumor-metastasis pairs (n = 34), tumor–LN
metastasis pairs (n = 24), tumor-distant metastasis (n = 10), autopsy
patient metastases from multiple organs within the same patient
(n = 33), metachronous tumor–metastasis pairs (n = 10), or from
independent patient samples; normal breast (n = 17), luminal A
tumors (n = 86), luminal B tumors (n = 50), HER2-enriched tumors
(n = 25), basal-like tumors (n = 44), claudin-low tumors (n = 45),
LN metastases (n = 21), and distant metastases (n = 45). b ICC of
298 gene expression signatures/modules [12] using the same samples
and pairing used in (a)
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123[6]. Since claudin-low and basal-like tumors were associ-
ated with brain relapse, we postulated that the more
undifferentiated a tumor is on this axis, the more likely it
would be to metastasize to the brain. To test this hypoth-
esis, gene expression data from parental and organ-tropic
(brain, lung, and bone) MDA-MB-231 cell lines were
obtained from the Gene Expression Omnibus, and their DS
calculated and plotted on the DS axis (Fig. 4a). Shown on
the same scale are the 779 breast tumor dataset (Fig. 4b),
cancer cell lines of various tissue origins (NCI60) [21]
(Fig. 4c), and the MDA-MB-231 series [16, 20, 22]
(Fig. 4d). Overall, claudin-low and luminal breast cancer
cells lines show the same relative differences in differen-
tiation status as is seen in primary tumors. Importantly, the
MDA-MB-231 cells from the NCI60 and Massague ´ studies
showed nearly identical DS, and the brain-tropic MDA-
MB-231 cells were signiﬁcantly less differentiated than the
parental cell line.
To identify other features shared between low DS
tumors and brain metastasis, we analyzed the NCI60 [21]
cell line series. Interestingly, DS were found to be similar
in claudin-low breast cancer cell lines, central nervous
system (CNS), and melanoma cell lines, a tumor type
known to aggressively spread to the brain[23] (Fig. 4c). To
identify genes that mediate cerebral colonization, signiﬁ-
cance analysis of microarrays (SAM) was performed on the
NCI60 data set by comparing these three cancer cell line
types versus the rest. Two-hundred and sixty-ﬁve genes
were identiﬁed as being highly expressed (FDR = 0%) in
claudin-low, CNS and melanoma cell lines; Ingenuity
Systems Pathway Analysis found that ‘‘cellular move-
ment’’ was the top biological function associated with these
genes (Supplemental Fig. 4).
The triple-negative SUM149PT breast tumor-derived
cell line contains two distinct populations of breast cancer
cells[24], which can be separated by FACS to yield one
population with basal-like and another with claudin-low-
like features and a lower DS [6]. To test if lower DS cor-
relates with increased migration, we ﬂuorescence-activated
cell sorted (FACS) the SUM149PT cell line into CD49f
?/
Epcam
-/low and CD49f
?/high/Epcam
? subpopulations,
performed Boyden chamber migration assays, and deter-
mined that the less differentiated (i.e., lower DS)
SUM149PT CD49f
?/Epcam
-/low cells were signiﬁcantly
(P\0.001) more migratory than the more differentiated
Epcam
? population (Supplemental Fig. 5).
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Fig. 2 Association of breast cancer subtype with site of ﬁrst relapse.
Shown are Kaplan–Meier plots and log rank tests of ﬁrst site of
relapse in each breast tumor subtype in the 779 tumor dataset. If a
patient showed two or more simultaneous sites of relapse, then this
patient was counted as being site of ﬁrst relapse for both. Organ of
ﬁrst relapse; a any, b brain, c lung, d bone, e liver
b
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123Differentiation Scores and metastasis
We next sought to better understand the information that
DS provides for predicting site of metastasis. Since there is
a range of differentiation within each intrinsic subtype
(Fig. 4b), we tested if the least differentiated basal-like/
claudin-low tumors were more metastatic than the more
differentiated basal-like/claudin-low tumors. Kaplan–Me-
ier analysis and log-rank tests determined that the least
differentiated half of these tumor subtypes were associated
with signiﬁcantly more relapse to brain (P = 2E-03, log
rank-test) and lung (P = 2.4E-02). This same approach
applied within luminal and HER2-enriched tumors found
no association of DS with bone or liver relapse, thus this
association appears speciﬁc for brain and lung relapses,
although it should be noted that the least differentiated
luminal and HER2-enriched tumors do not have low
overall DS.
To visualize the information that DS and intrinsic sub-
types provide for predicting site of metastasis, we plotted
the DS of the 779 tumors versus the HR for each site of
metastasis (Fig. 5a). The tumors were then ordered based
on DS and all genes (11,068) hierarchical clustered
(Fig. 5b). Interestingly, tumors with the lowest DS have a
much higher HR for brain and lung metastases, and this
risk drops off quickly as differentiation increases. Impor-
tantly, this analysis identiﬁed a subset of tumors within the
largely ER- claudin-low and basal-like tumors that
aggressively metastasize.
Stem cell signatures correlate with brain
and lung metastases
Several studies have shown an association of stem cell
characteristics and metastatic proclivity [25–27]. There-
fore, the 855 tumor dataset was used to test if several
Table 1 Site of ﬁrst relapse of the 779 tumors from each cohort according to intrinsic subtype
Cohort Subtype # of tumors % that relapsed Site of ﬁrst relapse (%)
Brain Lung Bone Liver LN
EMC192 Basal 40 90.0 8.3 41.7 30.6 19.4 NA
Claudin-low 23 73.9 17.6 41.2 35.3 17.6 NA
HER2 32 100.0 9.4 18.8 62.5 59.4 NA
Luminal A 57 89.5 2.0 7.8 76.5 31.4 NA
Luminal B 31 90.3 3.6 17.9 71.4 14.3 NA
EMC286 Basal 45 37.8 23.5 47.1 41.2 17.6 NA
Claudin-low 32 28.1 22.2 33.3 44.4 22.2 NA
HER2 54 38.9 9.5 14.3 76.2 28.6 NA
Luminal A 72 22.2 0.0 18.8 87.5 0.0 NA
Luminal B 49 46.9 8.7 34.8 87.0 13.0 NA
MSK82 Basal 17 29.4 20.0 100.0 40.0 NA NA
Claudin-low 10 50.0 20.0 100.0 40.0 NA NA
HER2 10 20.0 50.0 50.0 50.0 NA NA
Luminal A 23 30.4 14.3 14.3 57.1 NA NA
Luminal B 16 18.8 0.0 0.0 100.0 NA NA
NKI295 Basal 38 36.8 28.6 42.9 35.7 57.1 42.9
Claudin-low 25 28.0 28.6 42.9 42.9 57.1 0.0
HER2 48 43.8 23.8 33.3 71.4 57.1 28.6
Luminal A 91 11.0 30.0 10.0 70.0 30.0 30.0
Luminal B 66 40.9 22.2 18.5 74.1 44.4 25.9
Combined Basal 140 51.4 16.7 47.2 34.7 28.1 42.9
Claudin-low 90 42.2 21.1 47.4 39.5 23.1 0.0
HER2 144 52.8 14.5 22.4 68.4 59.7 28.6
Luminal A 243 34.6 6.0 10.7 76.2 23.5 30.0
Luminal B 162 50.0 11.1 22.2 77.8 22.6 25.9
Any subtype 779 45.1 12.8 27.4 62.7 29.1 27.8
Several tumors had multiple ﬁrst relapses: basal-like 22/69, claudin-low 12/44, HER2-enriched 35/64, luminal A 19/88, luminal B 31/86, and
these were thus counted as being sites of ﬁrst relapse for each site
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123previously published stem cell signatures contained within
our set of 298 gene modules [12] were associated with site
of relapse. Univariate Cox proportional hazards models
identiﬁed that many of the signatures with the strongest
associations for brain (and lung) relapse were either
expressed in normal brain and/or have been identiﬁed as
essential components of embryonic stem cells and tumor
initiating cells [26, 27] (Supplemental Table 4). Of the 13
embryonic stem cell signatures analyzed in Ben-Porath
et al. [27], all were signiﬁcantly associated with relapse to
brain/lung, 11 with LN metastasis, 10 with liver, and 5 with
bone. Nearly all the signatures that predicted for brain
relapse correlated with low DS, and those not strongly
correlated with DS were correlated with proliferation.
Some of these signatures further identiﬁed subsets of basal-
like and claudin-low tumors most likely to metastasize to
the brain (log-rank test: PRC2_targets; P = 0.0090,
MM_WapINT3; P = 0.0001). Thus, ES cell signatures,
DS, and proliferation appear to be strong predictors of CNS
and lung metastases, and in general, the signatures most
predominant for brain/lung relapse were weakly expressed
in tumors that spread to the bone.
Univariate and multivariable survival analyses
The ability to predict the presence and/or location of a
tumor recurrence could inﬂuence the location and fre-
quency of radiographic surveillance for patients with a
history of breast cancer. Therefore, we sought to identify
the most informative signature, or combination of signa-
tures that predicts metastasis to speciﬁc sites. First, we
performed univariate survival analyses for multiple signa-
tures, including the many described above and our previ-
ously published VEGF/hypoxia signature [28]. As shown
in Table 2A, all signatures tested were highly prognostic
overall and, interestingly, both BrMS and LMS signatures
predicted lung and brain relapse, providing evidence that
metastases to these two organs utilize similar genetic
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Fig. 3 Association of the brain (BrMS) and lung (LMS) cell line-
based metastasis signatures with intrinsic subtype. Box-and-whisker
plots are shown for each signature on multiple breast tumor
microarray data sets according to intrinsic subtype. P values were
calculated with ANOVA. Shown are the same data sets used for the
testing of the BrMS (a) or LMS (c) signatures, as well as an
independent UNC dataset (b, d)
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123mechanisms. Second, we performed multivariate analysis
using the backward stepwise procedure and observed that
subtype information (i.e., subtype calls or risk of relapse
categories based on subtype [ROR-S]) was selected in each
evaluation (Table 2B). For liver relapse, speciﬁcally,
knowing the subtype call instead of the ROR-S risk cate-
gory was found particularly informative; indeed, the risk of
liver relapse of the HER2-enriched subtype was 4.0 times
higher compared to the luminal A subtype despite that the
HER2 status (as determined by gene expression) was also
included. In addition to intrinsic subtype information, other
signatures were found statistically signiﬁcant in the various
MVA ﬁnal models, such as the upregulated genes of the
BrMS in brain relapse, or the VEGF/hypoxia signature and
the downregulated genes of the LMS in lung relapse.
Interestingly, the BrMS and VEGF/hypoxia-signature were
found highly correlated with DS (Pearson =- 0.68), and
correspondingly, the BrMS, DS, and VEGF/hypoxia-sig-
nature identify a subset of basal-like/claudin-low tumors
that spread to the brain (P\0.05). Thus, when each
metastatic site is individually examined, a unique combi-
nation of signatures is chosen that includes intrinsic sub-
type (individual subtype or ROR-S) as well as another
signature or two, ultimately resulting in the optimal set of
variables for predicting relapse to that organ.
Discussion
Metastases are the main cause of death for breast cancer
patients and predicting a tumor’s likelihood to spread, and
organ of relapse, is clinically important information.
Analysis of 265 breast tumors and 85 metastases found that
a breast tumor’s overall gene expression phenotype is lar-
gely maintained in its metastases. The gene expression
differences that do occur may be due to a combination of
different amounts of epithelial/stromal cells (Fig. 1, Sup-
plemental Table 1), and/or clonal expansion of a more
aggressive subclone of a tumor [4, 29]. The microenvi-
ronment also effects gene expression and response to
therapeutics [30], therefore, targeting the host organ cells,
vascular cells, as well as tumor cell speciﬁc targets may be
the best approach to inhibit disease progression [31]. This
overall similarity, however, does suggest that important
information about metastatic potential can be revealed by
studying primary tumors.
Basal-like and claudin-low breast cancers both exhibit a
high probability to metastasize to the brain and lung while
HER2-enriched subtype tumors preferentially colonize the
liver (Fig. 2; Table 1). The basal-like and claudin-low
tumor types are genomically related [6], exhibit similar
treatment response characteristics, and as shown here, have
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Fig. 4 Differentiation Score analysis of the 779 human breast
tumors, NCI60 cell lines, and MDA-MB-231 cell lines. a Differen-
tiation axis diagram based on FACS fractions Lim et al. [8], which is
described in Prat et al. [6]. b Box-and-whisker plots of the
distributions of scores from the 779 tumor dataset according to
intrinsic subtype. c NCI60 cancer cell lines gene DS values [21], with
the breast cancer cell lines divided into claudin-low (dashed circle
value for MDA-MB-231) or luminal cell lines. d MDA-MB-231
parental, lung-tropic, brain-tropic, and bone-tropic cell lines from the
studies of Massague ´ and colleagues. The asterisk indicates statistical
signiﬁcance difference in DS between parental and brain-tropic lines
(T test P = 0.002)
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123similar metastasis patterns. The CD49f
?/Epcam
-/low frac-
tion of the SUM149PT cell line (which is enriched for
claudin-low tumor features) was signiﬁcantly more
migratory than the more differentiated basal-like compo-
nent cells. Interestingly over time, the SUM149PT cells
with claudin-low characteristics asymmetrically divide into
two distinct populations of more (i.e., basal-like) and less-
differentiated cells, whereas the more differentiated frac-
tion produces similarly differentiated cells [6]. Since the
less-differentiated claudin-low-like cells contain higher
levels of genes that facilitate cellular movement (Supple-
mental Figs. 4, 5), we hypothesize that these cells may
initiate the metastatic cascade; after seeding a host organ,
they asymmetrically divide, spawning both more and less
differentiated cells. Precisely why these cells show predi-
lection for the brain and lung requires further investigation,
however, the cell line studies of Massague ´ and colleagues
using the claudin-low MDA-MB-231 cells are providing
for some initial candidates. These studies have shown that
the cells that are relatively more capable of spreading to the
CNS express genes that function to increase cellular
extravasation and blood brain barrier penetration [16],
while also upregulating glycolytic pathways and increasing
vascularization [28].
Our re-analyses of the data presented by Bos et al. [16]
ﬁnd that the DS of brain-tropic breast cancer cells is sig-
niﬁcantly lower than the parental cell line (Fig. 4); corre-
spondingly, low DS was also found to associate with brain
relapse in patients (Fig. 5). While basal-like and claudin-
low breast tumors can relapse in bone, recurrence in vital
organs, such as the brain and lung is more symptomatic.
Thus, ﬁrst site of recorded relapse for basal-like and
claudin-low tumors is typically not bone. DS, however, is
not the only factor that determines metastagenicity. For
example, luminal A and B tumors have similar DS, yet
luminal B tumors are much more likely to relapse. Perhaps
all luminal tumors can effectively seed certain organs,
however, the faster proliferation rate inherent to luminal B
tumors accounts for the differential relapse frequency.
Correspondingly, 58% of luminal B tumors present with
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123multiple organs as ﬁrst relapse events, compared to only
21% from luminal A.
After observing the metastasis patterns of the less-dif-
ferentiated basal-like and claudin-low breast tumors, it was
not surprising that the BrMS and LMS signatures associate
with subtype and DS. The BoMS was not strongly
expressed in any subtype, a ﬁnding which may reﬂect the
fact that bone was the most common site of metastasis in
our study. These ﬁndings complement analyses by Culhane
and Quackenbush [32] who found that a different lung
metastasis signature [33] was a surrogate for the basal-like
subtype. This does not argue, however, that these signa-
tures are not biologically important. In fact, the BrMS
identiﬁes some of the least differentiated tumors within the
claudin-low and basal-like subtypes and these data support
continued investigation of select genes within the BrMS as
targeting these genes, along with others that function to
increase cellular differentiation, may serve to slow meta-
static progression.
To gain a mechanistic understanding for site-speciﬁc
tumor colonization, we tested a compendium of 298
expression signatures as individual predictors of site of
relapse. These analyses showed enrichment for stem cell
signatures in brain/lung relapse (Supplemental Table 4).
The majority of these signatures provide information that is
encoded within DS; however, some of the signatures fur-
ther divide ER-negative tumors into two distinct groups
that are more or less likely to metastasize to the brain/lung.
As an example, one such signature is the MM_WapINT3,
which is a signature derived from a transgenic mouse
mammary tumor model that over-expresses Notch4 and
aggressively spreads to the lung [34]. This is a clinically
relevant ﬁnding in that half of patients with advanced triple
negative breast cancer relapse within the brain [35], and
survival following CNS relapse is less than 4 months [36],
regardless of receipt of systemic therapy.
Overall, the results from Table 2 reveal shared and
unique features predicting relapse to distinct sites. For
example, intrinsic subtype (as represented by individual
subtypesortheROR-Sscore)makeeveryﬁnalMVAmodel,
buttheneachsiteofrelapseshowsindividualcharacteristics.
For brain, the BrMS signature and HER2 status add
important information, while for lung the VEGF/hypoxia
and LMS signature add information, for bone the DS score
was valuable, and for liver, most information was carried by
the HER2-enriched subtype; thus for the most accurate site
of metastasis predictions, multiple signatures and/or clinical
variables are needed. Our ability to predict patients at the
highest risk for CNS relapse may impact the manner in
which we approach CNS screening and future prevention
strategies. The data presented herein provides clinically
useful information that could be used to identify patients
most likely to experience site-speciﬁc breast cancer relapse.
Materials and methods
Human breast tumor microarray datasets
Twodistinctmicroarraydatasetswerestudiedhere.Theﬁrst
was based upon Agilent Technologies DNA microarrays
taken from Prat et al., with 42 new additional metastasis
samplesproﬁledhere usingidenticalprotocolsaspreviously
described [6, 19, 37]. All human tumor and normal tissue
samples were collected using IRB-approved protocols and
all microarray and patient clinical data are available at UNC
Microarray Database (https://genome.unc.edu) and have
been deposited in the Gene Expression Omnibus (GEO)
under the accession number GSE26338. The probes/genes
for these analyses were ﬁltered by requiring the Lowess
normalized intensity values in both sample and control to be
[10. All probes for each gene were averaged. The normal-
izedlog2ratios(Cy5sample/Cy3control)ofprobesmapping
to the same gene (Entrez ID as deﬁned by the manufacturer)
wereaveragedtogenerateindependentexpressionestimates.
The second data consisted of a combined microarray data
set of four studies taken from the public domain. We utilized
the microarray as presented in the following breast cancer
datasets: GSE2034, GSE12276, GSE2603, and the NKI295
(microarray-pubs.stanford.edu/wound_NKI/Clinical_Data_
Supplement.xls). The clinical data from these patients was
obtained from previous studies [16, 38]. NCI60 cell line
microarray data was obtained from http://genome-www.
stanford.edu/nci60/. Additional microarrays from the GEO
for the MDA-MB-231 cells were downloaded from
GSE12237 and GSE2603. Probes in these external sets were
assignedtoEntrezGeneidentiﬁersandreplicategenenames
were collapsed to the median. The data from the four tumor
datasets were then combined using Distance Weighted
Discrimination [14] to remove the systematic biases present
indifferentmicroarraydatasets.Inalldatasets,sampleswere
standardized to zero mean and unit variances before other
analyses were performed.
Microarray data processing
Samples in the ﬁnal normalized data were assigned to the
ﬁve subtypes (luminal A, luminal B, Her2-enriched, basal-
like, and normal-like) using the PAM50 classiﬁer [19].
Assignment of claudin-low and DS were performed
according to the protocol described in Prat et al. [6]. 298
gene expression modules ﬁrst characterized in Fan et al.
[12] were applied to both data sets and expression esti-
mates obtained for each tumor in each data set; the gene list
corresponding to each module was summarized to the
mean expression within each sample, or the principal
component, or according to a predetermined algorithm.
Testing for differential expression of the modules between
Breast Cancer Res Treat (2012) 132:523–535 533
123primary and metastatic pairs from the same individual was
performed with the SAM [39] two class paired test.
Statistics and survival analyses
The intra-class correlation (ICC) [40] was utilized to esti-
mate concordance within speciﬁc groups of samples. For
groups of paired samples, the ICC was calculated for each
pair and then summarized by the mean ICC for each group
of interest. ICC values for groups of unpaired samples were
estimated from all samples in the group. ICC estimates
were performed identically for the set of modules or the set
of all genes. All ICC estimates were generated using the R
package ‘‘irr.’’ Principal components analyses were per-
formed in R. Categorical survival analyses were performed
using a log-rank test and visualized with Kaplan–Meier
plots. Box-and-whisker plots were used to observe the
relationship of the intrinsic subtypes with the organ-spe-
ciﬁc metastasis signatures and were performed in R. Uni-
variate and multivariable Cox proportional hazard analyses
were used to estimate HR and determine the signiﬁcance of
the intrinsic subtypes and gene signatures. Subtypes and
DS were compared along with ER status and published
signatures using time to ﬁrst relapse (for each site) as the
end point. To visualize the association of DS with Subtype
and site of metastasis HR for each site of metastasis were
identiﬁed by using a sliding window of 50 samples with
consecutive DS, and the HR was calculated by contrasting
the samples in the window versus those outside the win-
dow. HR estimates were smoothed across DS with Lowess.
Functional analysis of gene sets
261 genes that were differently expressed in the three
undifferentiated NCI 60 cell lines (as compared to the rest)
were uploaded into Ingenuity Systems Pathway Analysis
(www.ingenuity.com) based on their Entrez gene identiﬁ-
cation number.
Boyden chamber migration assays
SUM149PT cells were ﬂuorescence associated cell sorted
after immunolabeling with CD49f and Epcam as previ-
ously described [6]. CD49f
?/high/Epcam
? and CD49f
?/
Epcam
-/low cells were plated in 0% FBS Boyden chambers
with 8.0lm pores and chemoattracted to 0.5% FBS for
24 h. Migrated cells were stained with crystal violet, and
then solubilized and read at 470 nm.
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